文献速递前列腺癌

微超声靶向前列腺穿刺活检中增加穿刺针数的价值

Value of Incremental Biopsy Cores for Microultrasound Targeted Prostate Biopsies.
PubMed 文献 · Urology · 2023-12-03

该回顾性研究纳入2021年9月至2023年7月共1011例患者,其中536例接受微超声活检,475例接受磁共振/超声靶向活检。结果显示,对微超声病灶行三针靶向活检可提高临床显著前列腺癌的检出率,作者建议考虑采用以提高诊断准确性。

要点

  • 微超声病灶首针靶向穿刺检出临床显著前列腺癌的比例为78.0%(46/59)。
  • 微超声+磁共振病灶首针检出比例为77.8%(63/81),磁共振/超声为78.8%(216/274)。
  • 微超声病灶首针与第三针总体检出率无显著差异,磁共振/超声则有显著差异。

核心结论

  • 对每个微超声病灶行三针靶向活检可提高临床显著前列腺癌的检出率,作者建议考虑采用以提高诊断准确性。

研究设计与样本

  • 回顾性研究,纳入2021年9月至2023年7月本机构连续1011例患者,其中536例接受微超声活检,475例接受磁共振/超声靶向活检。

主要发现

  • 微超声病灶首针靶向穿刺检出临床显著前列腺癌的比例为78.0%(46/59),微超声+磁共振病灶为77.8%(63/81),磁共振/超声病灶为78.8%(216/274)。
  • 微超声病灶首针与第三针总体检出率无显著差异(28.4% vs 36.4%,P = .12),微超声+磁共振病灶无显著差异(32.5% vs 41.8%,P = .06),磁共振/超声病灶有显著差异(42.5% vs 53.9%,P < .001)。
  • 微超声中PI-RADS 3和PRI-MUS 3病灶的首针检出率低于PI-RADS 5和PRI-MUS 5病灶(44.4% vs 85.4%,P = .01),微超声+磁共振中为65.2% vs 81.4%(P = .14),磁共振/超声中为60% vs 83.1%(P = .07)。

临床怎么用

  • 作者建议考虑对每个微超声病灶行三针靶向活检以提高临床显著前列腺癌的诊断准确性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the optimal number of cores needed during microultrasound-informed prostate biopsy for the detection of clinically significant prostate cancer (csPCa, defined as Gleason Grade Group ≥2). METHODS: A retrospective review of 1011 consecutive patients between September 2021 and July 2023 at our institution were identified; 536 underwent microultrasound biopsy and 475 underwent magnetic resonance imaging (MRI)/ultrasound (US) targeted biopsy. Lesions were given a Prostate Risk Identification using Microultrasound (PRI-MUS) score, with lesions PRI-MUS ≥3 targeted. MRI lesions were scored with Prostate Imaging-Reporting and Data System (PI-RADS) and lesions PI-RADS ≥3 were targeted. The primary outcome is the detection of csPCa stratified by number of cores. RESULTS: One hundred thirty-eight patients underwent targeted biopsies for microultrasound only lesions, 182 for microultrasound and MRI lesions and 426 underwent MRI/US for MRI lesions. The first targeted core detected 78.0% (46/59), 77.8% (63/81), and 78.8% (216/274) of csPCa for microultrasound, microultrasound+MRI, and MRI/US, respectively. Comparing first to third core, there was not a significant difference in overall detection of csPCa by microultrasound, though MRI/US was significantly different (28.4% vs 36.4% P = .12, 32.5% vs 41.8% P = .06, 42.5% vs 53.9% P < .001 for microultrasound, microultrasound+MRI, and MRI/US, respectively). PI-RADS 3 and PRI-MUS 3 lesions had lower first core detection rates compared to PI-RADS 5 and PRI-MUS 5 lesions (44.4% vs 85.4% P = .01, 65.2% vs 81.4% P = .14, 60% vs 83.1% P = .07 for microultrasound, microultrasound+MRI, and MRI/US, respectively). CONCLUSION: A three-core targeted biopsy per microultrasound lesion improves detection rate of csPCa and should be considered to improve diagnostic accuracy.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Albers P, Bennett J, Evans M, et al. Value of Incremental Biopsy Cores for Microultrasound Targeted Prostate Biopsies. Urology. 2023. PMID: 38052325. doi:10.1016/j.urology.2023.11.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。